Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 7
Submit an article Journal homepage
645
Views
53
CrossRef citations to date
0
Altmetric
Special Focus: Vaccine Adjuvants - Review

Combination of adjuvants: the future of vaccine design

Adele Mount CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia; CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia
,
Sandra Koernig CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia; CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia
,
Anabel Silva CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia; CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia
,
Debbie Drane CSL Limited, 45 Poplar Road, Parkville, Australia; CSL Limited, 45 Poplar Road, Parkville, Australia
,
Eugene Maraskovsky CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia; CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia
&
Adriana Baz Morelli CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia. [email protected]; CSL Research, Bio21 Institute, 30 Flemington Road, Parkville, Australia. [email protected]
Pages 733-746 | Published online: 09 Jan 2014

References

  • Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28(Suppl. 3), C25–C36 (2010).
  • Aurisicchio L, Ciliberto G. Patented cancer vaccines: the promising leads. Expert Opin. Ther. Pat. 20(5), 647–660 (2010).
  • Qu L, Lemon SM. Hepatitis A and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses. Semin. Liver Dis. 30(4), 319–332 (2010).
  • Marsili G, Remoli AL, Sgarbanti M, Perrotti E, Fragale A, Battistini A. HIV-1, interferon and the interferon regulatory factor system: an interplay between induction, antiviral responses and viral evasion. Cytokine Growth Factor Rev. 23(4–5), 255–270 (2012).
  • Singh Y, Kaul V, Mehra A et al. Mycobacterium tuberculosis controls microRNA-99b (miR-99b) expression in infected murine dendritic cells to modulate host immunity. J. Biol. Chem. 288(7), 5056–5061 (2013).
  • Blomgran R, Desvignes L, Briken V, Ernst JD. Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host Microbe 11(1), 81–90 (2012).
  • Woodworth JS, Shin D, Volman M, Nunes-Alves C, Fortune SM, Behar SM. Mycobacterium tuberculosis directs immunofocusing of CD8+ T cell responses despite vaccination. J. Immunol. 186(3), 1627–1637 (2011).
  • Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin. Biol. Ther. 7(8), 1275–1280 (2007).
  • Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9(4), 287–293 (2009).
  • Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19(17–19), 2673–2680 (2001).
  • Carter NJ, Plosker GL. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 22(5), 279–292 (2008).
  • Geeraedts F, Huckriede A. Influenza vaccines: what do we want and how can we get it? Adv. Exp. Med. Biol. 780, 161–174 (2011).
  • O’Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev. Vaccines 12(1), 13–30 (2013).
  • Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing a-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11(3), 349–366 (2012).
  • Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines 7(8), 1141–1150 (2008).
  • Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev. Vaccines 6(2), 133–140 (2007).
  • Szarewski A. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Rev. Vaccines 11(6), 645–657 (2012).
  • Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 33(4), 492–503 (2010).
  • Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543–547 (2011).
  • Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11(5), 373–384 (2010).
  • Harandi AM, Medaglini D, Shattock RJ; Working Group convened by EUROPRISE. Vaccine adjuvants: a priority for vaccine research. Vaccine 28(12), 2363–2366 (2010).
  • Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 227(1), 221–233 (2009).
  • Kabelitz D, Medzhitov R. Innate immunity–cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr. Opin. Immunol. 19(1), 1–3 (2007).
  • Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine 29(17), 3341–3355 (2011).
  • Querec T, Bennouna S, Alkan S et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203(2), 413–424 (2006).
  • Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S et al. Combination adjuvants: the next generation of adjuvants? Expert Rev. Vaccines 10(1), 95–107 (2011).
  • Heldwein KA, Liang MD, Andresen TK et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J. Leukoc. Biol. 74(2), 277–286 (2003).
  • Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 104(1), 22–27 (2013).
  • Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol. 10(4), 243–254 (2012).
  • Zaheer SA, Mukherjee R, Ramkumar B et al. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J. Infect. Dis. 167(2), 401–410 (1993).
  • Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 26(8), 447–454 (2005).
  • Geddes K, Magalhães JG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. Nat. Rev. Drug Discov. 8(6), 465–479 (2009).
  • Agnandji ST, Lell B, Fernandes JF et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med 367(24), 2284–2295 (2012).
  • Goldinger SM, Dummer R, Baumgaertner P et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8? T-cell responses in melanoma patients. Eur. J. Immunol. 42(11), 3049–3061 (2012).
  • Remarque EJ, Roestenberg M, Younis S et al. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naive adults. PLoS ONE 7(6), e38898 (2012).
  • Leroux-Roels I, Forgus S, De Boever F et al.; M72 Study Group. Improved CD4? T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 31(17), 2196–2206 (2013).
  • Van Braeckel E, Bourguignon P, Koutsoukos M et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin. Infect. Dis. 52(4), 522–531 (2011).
  • Sokal EM, Hoppenbrouwers K, Vandermeulen C et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr virus vaccine in healthy young adults. J. Infect. Dis. 196(12), 1749–1753 (2007).
  • Fourcade J, Kudela P, Andrade Filho PA et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J. Immunother. 31(8), 781–791 (2008).
  • Karbach J, Gnjatic S, Bender A et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int. J. Cancer 126(4), 909–918 (2010).
  • Sabbatini P, Tsuji T, Ferran L et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 18(23), 6497–6508 (2012).
  • Galluzzi L, Vacchelli E, Eggermont A et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 1(5), 699–716 (2012).
  • Luo Y, Knudson MJ. Mycobacterium bovis bacillus Calmette–Guérin-induced macrophage cytotoxicity against bladder cancer cells. Clin. Dev. Immunol. 2010, 357591 (2010).
  • Stewart JH 4th, Levine EA. Role of bacillus Calmette–Guérin in the treatment of advanced melanoma. Expert Rev. Anticancer Ther. 11(11), 1671–1676 (2011).
  • Wille-Reece U, Flynn BJ, Loré K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203(5), 1249–1258 (2006).
  • Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev. Vaccines 4(3), 329–350 (2005).
  • Hennessy EJ, Parker AE, O’Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 9(4), 293–307 (2010).
  • Vacchelli E, Galluzzi L, Eggermont A et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1(6), 894–907 (2012).
  • Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86(6), 973–983 (1996).
  • Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640), 394–397 (1997).
  • Kenny EF, O’Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine 43(3), 342–349 (2008).
  • Zhu Q, Egelston C, Vivekanandhan A et al. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc. Natl Acad. Sci. USA 105(42), 16260–16265 (2008).
  • O’Neill LA. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 29(1), 12–20 (2008).
  • Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769–776 (2005).
  • Roelofs MF, Joosten LA, Abdollahi-Roodsaz S et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52(8), 2313–2322 (2005).
  • Ghosh TK, Mickelson DJ, Fink J et al. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell. Immunol. 243(1), 48–57 (2006).
  • Hong X, Tong S. Cortical functional connectivity under different auditory attentional efforts. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2012, 6196–6199 (2012).
  • Lim SN, Kuhn S, Hyde E, Ronchese F. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy. J. Immunother. 35(9), 670–679 (2012).
  • Grossmann C, Tenbusch M, Nchinda G et al. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. BMC Immunol. 10, 43 (2009).
  • Zhu Q, Egelston C, Gagnon S et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Invest. 120(2), 607–616 (2010).
  • Whitmore MM, DeVeer MJ, Edling A et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 64(16), 5850–5860 (2004).
  • Wiley SR, Raman VS, Desbien A et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci. Transl. Med. 3(93), 93ra69 (2011).
  • Garin A, Meyer-Hermann M, Contie M et al. Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation. Immunity 33(1), 84–95 (2010).
  • Ichinohe T, Ainai A, Ami Y et al. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J. Med. Virol. 82(10), 1754–1761 (2010).
  • Ainai A, Ichinohe T, Tamura S et al. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J. Med. Virol. 82(3), 476–484 (2010).
  • Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239(1), 178–196 (2011).
  • Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122–1126 (2008).
  • Harris J, Sharp FA, Lavelle EC. The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. Eur. J. Immunol. 40(3), 634–638 (2010).
  • Fritz JH, Le Bourhis L, Sellge G et al. Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26(4), 445–459 (2007).
  • Traub S, von Aulock S, Hartung T, Hermann C. MDP and other muropeptides – direct and synergistic effects on the immune system. J. Endotoxin Res. 12(2), 69–85 (2006).
  • Schwarz H, Posselt G, Wurm P, Ulbing M, Duschl A, Horejs-Hoeck J. TLR8 and NOD signaling synergistically induce the production of IL-1β and IL-23 in monocyte-derived DCs and enhance the expression of the feedback inhibitor SOCS2. Immunobiology 218(4), 533–542 (2013).
  • Tada H, Aiba S, Shibata K, Ohteki T, Takada H. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect. Immun. 73(12), 7967–7976 (2005).
  • Uehara A, Yang S, Fujimoto Y et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell. Microbiol. 7(1), 53–61 (2005).
  • Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26(Suppl. 10), K53–K61 (2008).
  • Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33–34), 5937–5949 (2006).
  • Paavonen J, Jenkins D, Bosch FX et al.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369(9580), 2161–2170 (2007).
  • Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574), 1693–1702 (2007).
  • Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95(11), 1459–1466 (2006).
  • Han JE, Wui SR, Park SA et al. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice. Vaccine 30(28), 4127–4134 (2012).
  • Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20(1), 73–83 (2006).
  • Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 30(46), 6541–6550 (2012).
  • Gershon AA, Arvin AM, Levin MJ, Seward JF, Schmid DS. Varicella vaccine in the United States: a decade of prevention and the way forward. J. Infect. Dis. 197(Suppl. 2), S39–S40 (2008).
  • Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 30(20), 3126–3135 (2012).
  • Wui SR, Kim HK, Han JE et al. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice. Int. Immunopharmacol. 11(9), 1195–1204 (2011).
  • Grabenstein JD. Anthrax vaccine: a review. Immunol. Allergy Clin. North Am. 23(4), 713–730 (2003).
  • Bossi P, Tegnell A, Baka A et al.; Task Force on Biological and Chemical Agent Threats, Public Health Directorate, European Commission, Luxembourg. Bichat guidelines for the clinical management of anthrax and bioterrorism-related anthrax. Euro Surveill. 9(12), E3–E4 (2004).
  • Gu M, Hine PM, James Jackson W, Giri L, Nabors GS. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine 25(3), 526–534 (2007).
  • Tross D, Klinman DM. Effect of CpG oligonucleotides on vaccine-induced B cell memory. J. Immunol. 181(8), 5785–5790 (2008).
  • Rynkiewicz D, Rathkopf M, Sim I et al. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 29(37), 6313–6320 (2011).
  • Yang M, Yan Y, Fang M et al. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. Int. Immunopharmacol. 13(4), 408–416 (2012).
  • Gong M, Zhou J, Yang C et al. Insect cell-expressed hemagglutinin with CpG oligodeoxynucleotides plus alum as an adjuvant is a potential pandemic influenza vaccine candidate. Vaccine 30(52), 7498–7505 (2012).
  • Ghandi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation and emerging treatments. Lancet Infect. Dis. 4(12), 725–738 (2004).
  • Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microb. Rev. 22(1), 76–98 (2009).
  • Dasari V, Smith C, Zhong J, Scott G, Rawlinson W, Khanna R. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J. Gen. Virol. 92(Pt 5), 1021–1031 (2011).
  • Naarding MA, Falkowska E, Xiao H, Dragic T. Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice. Vaccine 29(16), 2910–2917 (2011).
  • Zhan N, Xiu BS, Wang GH et al. Enhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen. Virol. J. 8, 507 (2011).
  • Lee CJ, Lee LH, Frasch CE. Protective immunity of pneumococcal glycoconjugates. Crit. Rev. Microbiol. 29(4), 333–349 (2003).
  • Denoël P, Philipp MT, Doyle L, Martin D, Carletti G, Poolman JT. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 29(33), 5495–5501 (2011).
  • Philipp MT, Purcell JE, Martin DS et al. Experimental infection of rhesus macaques with Streptococcus pneumoniae: a possible model for vaccine assessment. J. Med. Primatol. 35(3), 113–122 (2006).
  • Safari D, Dekker HA, Rijkers G, Snippe H. Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates. Vaccine 29(4), 849–854 (2011).
  • Drane D, Boyle J, Maraskovsky E. ISCOMATRIXTM adjuvant for prophylactic and therapeutic vaccines. Expert Review of Vaccines 6(5), 761–772 (2005).
  • Duewell P, Kisser U, Heckelsmiller K et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J. Immunol. 187(1), 55–63 (2011).
  • Wilson NS, Yang B, Morelli AB et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol. Cell Biol. 90(5), 540–552 (2012).
  • Mckenzie A, Gittleson C. ISCOMATRIX® vaccines: safety in human clinical studies. Human Vaccines 6(3), 237–246 (2010).
  • Jacobs C, Duewell P, Heckelsmiller K et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int. J. Cancer 128(4), 897–907 (2011).
  • Middleton D, Rockman S, Pearse M et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J. Virol. 83(15), 7770–7778 (2009).
  • Simmons DP, Canaday DH, Liu Y et al. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J. Immunol. 185(4), 2405–2415 (2010).
  • Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5(8), 800–808 (2004).
  • Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol. 23(8), 375–378 (2002).
  • Belderbos ME, van Bleek GM, Levy O et al. Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin. Immunol. 133(2), 228–237 (2009).
  • Nguyen M, Leuridan E, Zhang T et al. Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS ONE 5(4), e10407 (2010).
  • van Duin D, Mohanty S, Thomas V et al. Age-associated defect in human TLR-1/2 function. J. Immunol. 178(2), 970–975 (2007).
  • Shaw AC, Panda A, Joshi SR, Qian F, Allore HG, Montgomery RR. Dysregulation of human Toll-like receptor function in aging. Ageing Res. Rev. 10(3), 346–353 (2011).
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252–264 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.